Targeting glutamate neurocircuitry as a means to identify new drugs for the treatment of schizophrenia has drawn considerable attention. We have investigated small molecule agonists that act at metabotropic glutamate receptors mGlu2 and mGlu3 to normalize aberrant glutamate neurotransmission thought to be associted with this disease. From this work, we identified LY404039, a potent, selective mGlu2/3 receptor agonist and a suitable oral prodrug, LY2140023.H2O (Pomaglumetad methionil). Preclinical and clinical findings associated with these molecules will be presented.

Activation of metabotropic glutamate 2/3 receptors as a new approach for the treatment of schizophrenia

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.